Skip to main content
. 2024 Jan 11;24:54. doi: 10.1186/s12877-024-04664-4

Table 1.

Baseline characteristics of 7,392 participants by body mass index category

Characteristic Underweight (n = 384) Normal weight (n = 2,999) Overweight (n = 1,556) Obese (n = 2,453) P Value a
Age, mean (SD), y 62.7 ± 9.5 58.4 ± 8.6 57.1 ± 8.1 56.3 ± 7.9 < 0.001
Male 217(56.5) 2275(59.3) 1065(47.3) 359(39.2) < 0.001
Rural residence 273(71.1) 2505(65.3) 1231(54.6) 453(49.5) < 0.001
Married 319(83.1) 3255(84.8) 1976(87.7) 817(89.2) < 0.001
Educational level < 0.001
 No formal education 81(21.1) 613(16.0) 334(14.8) 137(15.0)
 Primary school 195(50.8) 1796(46.8) 920(40.8) 370(40.4)
 Middle or high school 107(27.9) 1371(35.7) 957(42.5) 394(43.0)
 College or above 1(0.3) 59(1.5) 42(1.9) 15(1.6)
Smoking status b < 0.001
 Never 178(46.4) 1977(51.5) 1424(63.2) 640(69.9)
 Former 39(10.2) 343(8.9) 244(10.8) 95(10.4)
 Current 167(43.5) 1518(39.6) 585(26.0) 181(19.8)
Drinking status < 0.001
 Never 212(55.2) 1979(51.5) 1331(59.1) 584(63.8)
 Former 36(9.4) 322(8.4) 168(7.5) 80(8.7)
 Current 136(35.4) 1538(40.1) 754(33.5) 252(27.5)
History of comorbidities
 CVD 39(10.2) 438(11.4) 347(15.4) 194(21.2) < 0.001
 Diabetes b 8(2.1) 159(4.2) 202(9.1) 116(12.7) < 0.001
 Dyslipidemia b 15(4.0) 221(5.8) 330(14.9) 212(23.7) < 0.001
 Hypertension b 37(9.7) 697(18.2) 707(31.5) 426(46.6) < 0.001
 Chronic kidney disease b 33(8.6) 199(5.2) 138(6.1) 47(5.2) 0.027
History of medication use
 CVD medications 17(4.4) 210(5.5) 179(7.9) 112(12.2) < 0.001
 Diabetes medications b 0(0.0) 24(0.6) 23(1.0) 9(1.0) 0.085
 Hypertension medications b 25(6.5) 442(11.6) 515(23.0) 345(37.7) < 0.001
 Lipid-lowering therapy b 8(2.1) 99(2.6) 141(6.4) 110(12.3) < 0.001
Blood pressure, mean (SD), mm Hg b
 Systolic 125.4 ± 22.2 126.6 ± 20.0 132.8 ± 20.4 137.2 ± 21.1 < 0.001
 Diastolic 71.6 ± 12.1 73.9 ± 11.6 78.5 ± 11.8 81.5 ± 12.1 < 0.001
Metabolic biomarkers c
 Total cholesterol, mean (SD), mg/dL 186.2 ± 35.0 191.1 ± 37.1 197.3 ± 38.1 199.4 ± 39.5 < 0.001
 Triglycerides, median (IQR), mg/dL 85.0(65.5,108.9) 95.6(69.0,138.9) 123.9(87.6,180.5) 140.7(99.1,210.6) < 0.001
 High-density lipoprotein, mean (SD), mg/dL 61.0 ± 18.0 53.6 ± 15.6 47.1 ± 13.2 43.3 ± 12.1 < 0.001
 Low-density lipoprotein, mean (SD), mg/dL 107.9 ± 30.9 114.6 ± 33.6 120.6 ± 35.2 118.7 ± 36.8 < 0.001
 Fasting plasma glucose, mean (SD), mg/dL 104.2 ± 35.5 107.5 ± 34.5 113.7 ± 39.3 116.9 ± 38.5 < 0.001
 Estimated glomerular filtration rate, mean (SD), mL/min/1.73 m2 87.0 ± 20.1 88.2 ± 21.3 90.9 ± 21.8 93.9 ± 21.4 < 0.001
 High-sensitivity C-reactive protein, median (IQR), mg/L 0.8(0.4,1.9) 0.9(0.5,1.8) 1.1(0.6,2.1) 1.6(0.9,3.2) < 0.001
Cognitive scores at baseline 14.0 ± 4.5 15.1 ± 4.4 15.9 ± 4.3 16.0 ± 4.5 < 0.001

Abbreviation: SD, standard deviation. IQR, interquartile range (75th quartile minus 25th quartile). aP value was based on χ2 or analysis of variance or Mann-Whitney U test where appropriate. b Missing data: 11 for abdominal obesity, 1 for smoking, 46 for diabetes, 27 for hypertension, 106 for dyslipidemia, 19 for chronic kidney disease, 47 for diabetes medications, 27 for hypertension medications, 110 for lipid-lowering therapy, 80 for systolic blood pressure, and 83 for diastolic blood pressure. c Measured in a subpopulation of 5582 participants